Hancock Jaffe Laboratories, Inc.: First U.S. Patent Allowed on Hancock Jaffe VenoValve
IRVINE, CA / ACCESSWIRE / February 24, 2021 /
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the company s VenoValve. The patent, which focuses on novel aspects of the VenoValve frame, will be the first to issue among several VenoValve patent applications pending in the U.S. and throughout the world.
The VenoValve is a clinical stage device that is being developed to treat a debilitating condition known as chronic venous insufficiency (CVI) of the deep venous system. CVI occurs when valves inside the veins of the leg fail, causing blood to flow in the wrong direction (reflux), and increasing venous pressure (venous hypertension). This results in leg swelling, pain, open sores (venou
Hancock Jaffe Completes $41 Million Public Offering
phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Hancock Jaffe Laboratories Announces Pricing of Upsized $36 Million Offering
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.